Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe eye fluid to uncover why some macular degeneration patients Don't get better

NCT ID NCT03630562

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at proteins in the eye fluid of 100 people with wet age-related macular degeneration (AMD). The goal was to measure certain growth factors that might explain why about 37% of patients do not respond well to standard anti-VEGF injections. Researchers collected a small sample of fluid from the front of the eye during a routine procedure. The study did not test any new drug, but aimed to gather information that could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain why some patients with wet age-related macular degeneration do not improve with standard anti-VEGF injections.
What could go wrong
This is an observational study that only measures proteins in eye fluid; it does not test a new treatment. The findings may not lead to any change in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Nov 2018

Finished

Aug 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment. * Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months * Signature of informed consent * Affiliation to the French social security system Exclusion Criteria: * Pregnant or nursing patient (a urinary pregnancy test will be performed) * Systemic treatment with anti-VEGF * Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye. * Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis. * Diabetes Mellitus * High Myopia * Simultaneous participation in another clinical research protocol in exudative AMD * Person under guardianship, under curatorship, deprived of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration

Contacts and locations

Locations

  • Hôpital Pasteur 2 - Service d'Ophtalmologie

    Nice, 06001, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.